Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chesnara prices £150m of convertible notes

(Sharecast News) - Chesnara announced the successful pricing of £150m of fixed rate reset perpetual restricted tier one contingent convertible notes on Wednesday, as the life insurance consolidator looked to bolster its financial flexibility and pursue further acquisition opportunities. The London-listed firm said the notes, which would be issued on 1 August subject to customary conditions, carried an initial coupon of 8.5% until the first reset date.

It said the earliest call date was 1 August 2030.

Chesnara said the proceeds would be used for general corporate purposes, including investments and acquisitions.

The securities were expected to be listed on the Official List of Euronext Dublin and admitted to trading on its Global Exchange Market.

Fitch Ratings had assigned a BBB- rating to the notes with a stable outlook.

"At the time of the announcement of our proposed acquisition of HSBC Life UK, we stated that we continued to actively assess ways to optimise our financing options, including the issuance of restricted tier one instruments," said chief executive Steve Murray.

"Following the success of our recent £140m rights issue as part of the financing package for the HSBC Life UK transaction, we are delighted with the continued support from investors as we seek to ensure we maintain financial flexibility to pursue future acquisitions.

"We continue to see a positive pipeline of merger and acquisition opportunities."

At 1337 BST, shares in Chesnara were down 0.42% at 262.4p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.